<DOC>
	<DOCNO>NCT01162889</DOCNO>
	<brief_summary>This `` first human '' study determine safety tolerability drug single dos . Nine dose increase strength inject infused ( give vein ) 9 different group people . One third participant give injection infusion placebo ( sugar water ) . All participant healthy people .</brief_summary>
	<brief_title>Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 ( PF-05230900 ) In Healthy People</brief_title>
	<detailed_description>First human single dose study . Study terminate 12 October 2011 . The ATR-107 Development team reach recommendation terminate development ATR-107 ( PF-05230900 ) . This base number factor , include development anti-drug antibody approximately 70 % subject First-in-Human study healthy volunteer ( B2281001 ) . This recommendation base adverse event observe study B2281001 .</detailed_description>
	<criteria>Females nonchildbearing potential Body mass index 17.5 30.5 body weight &gt; 50 kg History significant medical illness Positive urine drug screen alcohol dependance Smoking &gt; 10 cigarette per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>Crohn 's disease</keyword>
</DOC>